Company: INTS
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001567264-25-000010
Chunk: 249

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 7A
Chunk 249
---
, by and between Intensity Therapeutics, Inc. and the purchasers party thereto (incorporated by reference to Exhibit 10.1 of our Form 8-K filed on November 22, 2024).

112

19.1*Insider Trading Policy.21.1List of subsidiaries of the Company (incorporated by reference to Exhibit 21.1 of our Form S-1 filed on June 29, 2023)23.1*Consent of Independent Registered Public Accounting Firm31.1*Certification of CEO Pursuant to Section 302 of the Sarbanes-Oxley Act of 200231.2*Certification of CFO Pursuant to Section 302 of the Sarbanes-Oxley Act of 200232.1**Certification of CEO Pursuant to Section 906 of the Sarbanes-Oxley Act of 200232.2**Certification of CFO Pursuant to Section 906 of the Sarbanes-Oxley Act of 200297.1Clawback Policy (incorporated by reference to Exhibit 97.1 of our Form 10-K filed on March 14, 2024)101.INS*Inline XBRL Instance Document101.SCH*Inline XBRL Taxonomy Extension Schema Document.101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document.101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document.101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document.101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document.104*Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

______________________________________

#   Indicates a management contract or compensatory plan or arrangement.

†Certain information has been excluded from the exhibit because it both (i) is not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.

*   Filed herewith.

** Furnished herewith.

ITEM 16. FORM 10-K SUMMARY

None

113

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Intensity Therapeutics, Inc.Date: March 13, 2025By:/s/ Lewis H. BenderLewis H. BenderPresident, Chief Executive Officer and Chairman